MAP2K7 and hematologic disorder: Furthermore, associating the integrated clusters with the pharmacological profiles of 24 anticancer drug compounds revealed selective sensitivity to MEK inhibitors in a subset of hematopoietic cell lines, a potentially clinically important finding that a subgroup of hematological malignancies may benefit from MEK inhibitors.39